Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26749036 | 0.96 | CES2 (0.57) | CES2HRH3 | |
| SCHEMBL14882779 | 0.94 | CES2 (0.59) | CES2HRH3GAA | |
| SCHEMBL26749030 | 0.92 | CES2 (0.57) | CES2HRH3 | |
| SCHEMBL26749058 | 0.92 | CES2 (0.62) | CES2HRH3 | |
| SCHEMBL26749033 | 0.90 | CES2 (0.55) | CES2HRH3 | |
| SCHEMBL26749019 | 0.88 | CES2 (0.58) | CES2HRH3 | |
| SCHEMBL26749082 | 0.88 | CES2 (0.57) | CES2HRH3 | |
| SCHEMBL26749079 | 0.88 | CES2 (0.52) | CES2HRH3 | |
| SCHEMBL26749077 | 0.86 | CES2 (0.48) | CES2GAA | |
| SCHEMBL26749062 | 0.83 | CES2 (0.45) | CES2HRH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | CES2 1693/4885HRH3 2453/4885GAA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.